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Chronic kidney disease is characterized by Vitamin D deficiency and activation of the renin-angiotensin-aldosterone system.
Increasing data show that vitamin D receptor agonists (VDRAs) exert beneficial effects in renal disease and possess anti-
inflammatory properties, but the underlying mechanism remains unknown. Emerging evidence suggests that “a disintegrin and
metalloproteinase” (ADAM)/epidermal growth factor receptor (EGFR) signalling axis contributes to renal damage. Aldosterone
induces EGFR transactivation regulating several processes including cell proliferation and fibrosis. However, data on tubular
epithelial cells is scarce.We have found that, in cultured tubular epithelial cells, aldosterone induced EGFR transactivation via TGF-
𝛼/ADAM17. Blockade of the TGF-𝛼/ADAM17/EGFR pathway inhibited aldosterone-induced proinflammatory gene upregulation.
Moreover, among the potential downstream mechanisms, we found that TGF-𝛼/ADAM17/EGFR inhibition blocked ERK and
STAT-1 activation in response to aldosterone. Next, we investigated the involvement of TGF-𝛼/ADAM17/EGFR axis in VDRA
anti-inflammatory effects. Preincubation with the VDRA paricalcitol inhibited aldosterone-induced EGFR transactivation, TGF-
𝛼/ADAM-17 gene upregulation, and downstream mechanisms, including proinflammatory factors overexpression. In conclusion,
our data suggest that the anti-inflammatory actions of paricalcitol in tubular cells could depend on the inhibition of TGF-
𝛼/ADAM17/EGFR pathway in response to aldosterone, showing an important mechanism of VDRAs action.
1. Introduction
One of the earliest pathologic features of chronic kidney
disease (CKD) patients is active vitamin D deficiency [1,
2]. Increasing data show that vitamin D receptor ago-
nists (VDRAs) therapy decreases proteinuria, may reduce
renal damage progression, and improves cardiovascular out-
comes in CKD patients [1–3]. These beneficial effects are
independent of serum parathyroid hormone, phosphorus,
and calcium levels suggesting that vitamin D presents
pleotropic actions, beyond mineral metabolism regulation
[1, 4]. Active vitamin D (1,25–dihydroxy vitamin D(3) or
calcitriol) mediates its biological effects by binding to the
vitamin D receptor (VDR), which then translocates to
the nuclei of target cells [1]. In experimental renal dis-
ease vitamin D or VDRAs treatment diminished fibrosis,
mesangial proliferation, podocyte loss, and inflammatory
cell infiltration [5–10]. However, the molecular mechanism
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Figure 1: Aldosterone induces EGFR phosphorylation in cultured tubular epithelial cells. Human tubular epithelial cells were treated (a)
with 1 𝜇mol/L aldosterone (Aldo) for increasing times or (b) with several concentrations (range 1–0.001𝜇mol/L Aldo) for 15min. (c) The
figure shows a quantification of time-course EGRF phosphorylation. The data are expressed as mean ± SEM of 4 independent experiments.
∗
𝑃 < 0.05 versus control.
involved in the anti-inflammatory effects of vitamin D in the
setting of CKD remains poorly characterized.
The renin-angiotensin-aldosterone system (RAAS) is a
major mediator of progressive renal injury in CKD, with
angiotensin II (AngII) and aldosterone (Aldo) being themost
relevant RAAS components [11, 12]. Both factors promote
renal inflammation, fibrosis, and podocyte injury [13–15].
There is a close relation between vitamin D and the RAAS.
The hormonal form of vitamin D is a negative endocrine
regulator of the RAAS by suppressing renin biosynthesis
[16]. Homozygous VDR knockout mice develop high renin
hypertension, cardiac hypertrophy, and increased susceptible
to kidney damage following unilateral ureteral obstruction
[17, 18]. Therefore, investigation of underlying mechanisms
implicated in the relation between RAAS and vitamin D
actions in CKD is an important field of research.
Emerging evidence suggests that blockade of epidermal
growth factor receptor (EGFR) can be a therapeutic option
for renal diseases. Experimental studies have shown that
genetic or pharmacological EGFR blockade ameliorates renal
disease progression, mainly by diminishing kidney fibro-
sis [19, 20]. Regarding the RAAS, both AngII and Aldo,
after binding to their specific receptors, can transactivate
EGFR, via “a disintegrin and metalloproteases” (ADAMs),
thus regulating cellular functions, including proliferation,
hypertrophy, andmigration [21–23]. ADAMs aremembrane-
spanning metalloproteases involved in cleavage of extracel-
lular substrates (shedding), including EGF family ligands,
both constitutively and in response to regulatory stimu-
lation [24, 25]. In the kidney, ADAM17, also known as
TACE, participates in the shedding of the EGFR ligands,
heparin binding EGF-like growth factor (HB-EGF), and
transforming growth factor-𝛼 (TGF-𝛼) [26–29]. Both lig-
ands are involved in AngII-induced EGFR transactivation,
although some differences have been described between cell
types and tissues [30]. In mice, ADAM17-mediated TGF-𝛼
shedding contributes to AngII-induced experimental renal
fibrosis [20]. Most of the studies on Aldo/EGFR pathway
have been done in cultured cells, mainly in vascular smooth
muscle cells [14] and in mesangial cells, the latter showing
a role in cell proliferation [31]. We now demonstrated here
that, in cultured tubular epithelial cells, Aldo activates the
EGFR pathway via ADAM-17/TGF-𝛼 shedding, leading to
upregulation of proinflammatory factors. These data are
in line with our recent observation that blockade of the
ADAM17/EGFR axis prevents experimental renal inflamma-
tion induced by systemic administration of the TWEAK
cytokine [32], showing that this pathway, besides regulating
proliferation and fibrosis, could contribute to renal inflam-
mation. Furthermore, we now show that the beneficial anti-
inflammatory effects of VDRAs such as paricalcitol in renal
disease may be explained by inhibition of Aldo-mediated
proinflammatory factors overexpression throughmodulation
of ADAM17/TGF-𝛼/EGFR signalling axis and dampening of
downstream mechanisms, including ERK and STAT-1 acti-
vation. Our data add novel information about mechanisms
involved in the well-known anti-inflammatory properties of
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Figure 2: ADAM17 inhibition blocks aldosterone-mediated EGFR activation in tubular epithelial cells. HK2 cells were transfected with an
ADAM17 siRNA or scrambled siRNA, as described in “methods,” before stimulation with 1𝜇mol/L Aldo for 15min. Phosphorylated-EGFR
levels were evaluated by Western blot using an antibody against Y1068 phosphorylated-EGFR (p-EGFR1068). GAPDH levels were used as
loading control and ADAM17 as silencing control. (a) Representative Western blot and quantification of data expressed as mean ± SEM of 4
independent experiments. ∗𝑃 < 0.05 versus untreated siRNA control-transfected cells control. #𝑃 < 0.05 versus Aldo-treated siRNA scramble
cells. (b) Cells were preincubated with the specific ADAM17 inhibitor TAPI-2 (50𝜇mol/L) for 1 hour and then stimulated with 1 𝜇mol/L Aldo
for 15min. RepresentativeWestern blot and data expressed asmean ± SEMof 4 independent experiments. ∗𝑃 < 0.05 versus control. #𝑃 < 0.05
versus Aldo.
VDRAs and contribute to better design of future clinical
trials.
2. Material and Methods
2.1. Cultured Cells. Human kidney proximal tubule epithe-
lial cells (HK2 cell line, ATCC CRL-2190) were grown
in RPMI 1640 with 10% fetal bovine serum (FBS), 1%
glutamine, 100U/mL penicillin, 100𝜇g/mL streptomycin,
5 𝜇g/mL insulin-transferrin-selenite, and 36 ng/mL hydro-
cortisone in 5% CO
2
at 37∘C. When cells reached 60 to 70%
confluence, they were incubated in serum-free medium for
24 hours before the experiments.
Tubuloepithelial proximal murine cells (MCT cell line)
were originally obtained from Dr. Eric Neilson (Vanderbilt
University) and used for gene expression studies. These cells
were grown in RPMI 1640 with 10% FBS, 1% glutamine,
100U/mL penicillin, and 100 𝜇g/mL streptomycin in 5% CO
2
at 37∘C. When reached 60 to 70% confluence, they were
maintained in RPMI with 1% FBS for 24 hours.
Cells were treated with recombinant Aldo (1 𝜇mol/L;
Sigma). In some experiments cells were preincubated for
1 hour with the following inhibitors prior to stimulation:
the EGFR kinase inhibitor AG1478 (100 nmol/L), the ERK
inhibitor U0126 (10 𝜇mol/L; Calbiochem), TAPI-2, a specific
inhibitor of ADAM-17 (50𝜇mol/L, Enzo Life Sciences), and
a specific inhibitor of HB-EGF, CRM197 (10𝜇g/mL, Sigma).
In some experiments, cells were preincubated for 24 hours
with a neutralizing antibody anti-TGF-𝛼 (2.5 𝜇g/mL, Abcam)
and for 48 hours with paricalcitol (12 𝜇mol/L, Abbott).
DMSO was used as a solvent in many of these reagents but
had no effect on cell viability or on gene expression levels
(data not shown).
2.2. Protein Studies. The EGFR phosphorylation status was
analysed by Western blotting. Briefly, proteins were obtained
using lysis buffer [50mmol/L Tris-HCl and 150mol/L NaCl;
2mmol/L EDTA, 2mmol/L EGTA, and 0.2% Triton X-
100, 0.3% IGEPAL; 10 𝜇L/mL protease inhibitor cocktail;
10 𝜇L/mL PMSF and 10 𝜇L/mL orthovanadate]. Protein con-
tent was quantified by the BCA method, using bovine serum
albumin (BSA) as standard. Cell lysates (25 𝜇g/lane) were
separated on 6% to 12% SDS-polyacrylamide gels under
reducing conditions. Samples were transferred to nitrocel-
lulose membranes (Bio-Rad), blocked in 50mmol/L Tris-
HCl, pH 7.5, 150mmol/L NaCl, 0.05% Tween-20, and 5%
milk, and incubated overnight at 4∘C with the following
antibodies [dilution]: anti-phosphorylated-EGFR on Tyro-
sine (Y) 1068 (p-EGFR
1068
) [1 : 250] (Calbiochem), ADAM17
[1 : 1000] (Abcam), EGFR [1 : 250], p-ERK1/2 [1 : 200] (Santa
Cruz Biotechnology), and p-STAT1 [1 : 500] (Invitrogen).
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Figure 3: Aldosterone regulates genes expression of ADAM17 (a), TGF-𝛼, and HB-EGF (b). Cells were treated with 1𝜇mol/L Aldo for
increasing times and gene expression levels were evaluated by real-time PCR. Data are expressed as mean ± SEM of 3 independent
experiments. ∗𝑃 < 0.05 versus control.
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Figure 4: Aldosterone transactivates EGFR via TGF𝛼, but not HB-EGF, shedding. Cells were pretreated for 24 h with a neutralizing antibody
against TGF𝛼 (2.5 𝜇g/mL) (a) or 1 hourwith theHB-EGFpharmacological inhibitorCRM197 (10𝜇mol/L) (b) before stimulationwith 1𝜇mol/L
Aldo for 15min. Western blot experiment and data are expressed as mean ± SEM of 3 or 5 independent experiments, respectively. ∗𝑃 < 0.05
versus control. #𝑃 < 0.05 versus Aldo.
Subsequently, membranes were incubated with a peroxidase-
conjugated secondary antibody and developed using the ECL
chemiluminescence kit (Amersham Pharmacia Biotech).
Protein quality and transfer efficiency were assessed by
Ponceau red staining (not shown). To assess protein loading,
membranes were incubated with anti-GAPDH [1 : 10000]
(Chemicon International). Total proteins were used as con-
trol for phosphorylation studies. Films were scanned using
theGelDocEZmachine imager and analysed using the Image
Lab 3.0 (Bio-Rad).
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Figure 5: ADAM17/TGF-𝛼/EGFR signaling blockade inhibits aldosterone-mediated proinflammatory factors upregulation. Cells were
pretreated with the specific ADAM17 inhibitor TAPI-2 (50𝜇mol/L; 1 hour), a neutralizing antibody against TGF𝛼 (2.5 𝜇g/mL, 24 hour),
the EGFR kinase inhibitor AG 1478 (100 nmol/L, 1 hour), or the ERK inhibitor U0126 (10 𝜇mol/L; 1 hour) before stimulation with 1 𝜇mol/L
Aldo for 6 hours. CCL-2 and CCL-5 gene expression levels were determined by real-time PCR. Data are expressed as mean ± SEM of 2-3
experiments. ∗𝑃 < 0.05 versus control. #𝑃 < 0.05 versus Aldo.
2.3. Gene Silencing. The ADAM-17 gene was silenced using
an interference silencer siRNA or its corresponding scramble
control (Ambion). Subconfluent cells were transfected for
24 hours with 25 nmol/L siRNA using 50 nmol/L of Lipo-
fectamine RNAiMAX (Invitrogen), according to the man-
ufacturer’s instructions. Subsequently, cells were incubated
with 10% FBS heat inactivated for 24 hours. Then, cells were
incubated in serum-free medium for 24 hours before the
experiment. The specificity and efficiency of silencing were
checked by Western blot with an anti-ADAM-17 antibody
(AbCam) [1 : 1000].
2.4. Gene Expression Studies. Total RNA was isolated in
Trizol (Invitrogen, Groningen, Netherlands) from samples
and mouse kidney cells. cDNA was synthesized using the
High Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA) using 2 𝜇g of total RNA with random
hexamer primers, following the manufacturer’s instructions.
We performed real-time PCR expression using probes
(Taqman probes labelled with FAM fluorophore) from
Applied Biosystems: VDR Mm 00437297 m1; ADAM-
17 Mm 00456428 m1; CCL-2 Mm00441242 m1; CCL-5
Mm 01302428 m1; TGF-𝛼 Mm 00446232 m1. Data
were normalized to 18S ribosomal RNA of eukaryotic:
4210893E (VIC). The number of copies of mRNA for each
sample was calculated by the instrument software using
the Ct. value (shaped point arithmetic analysis on the
thermocycler). The results were expressed in relative copy
number calculated relative to unstimulated cells or control
mice, after normalization to 18S.
2.5. Statistical Analysis. The results shown in the text are
expressed as mean ± SEM. The differences between the
groups treated with agonists and controls were evaluated by
the Student’s 𝑡-test and Mann-Whitney test, and 𝑃 < 0.05
was considered significant. Statistical analysis was performed
using SPSS statistical software (version 11.0, Chicago, IL).
3. Results
3.1. Aldosterone Induces EGFR Transactivation via ADAM17
and Subsequent Release of TGF-𝛼 in Cultured Tubular Epithe-
lial Cells. Aldo induced EGFR transactivation in several cells,
including epithelial cells and mesangial cells [31, 33]. In
cultured human tubular epithelial cells (HK2 cell line), Aldo
induced a rapid activation of EGFR, as shown by increased
EGFR phosphorylation on Tyr1068, in a time and dose-
dependent manner, presenting a maximal effect at 1𝜇mol/L
Aldo after 10min (Figures 1(a), 1(b) and 1(c)). The blockade
of ADAM17, by gene silencing or pharmacological inhibition
using TAPI-2, markedly diminished Aldo-induced EGFR
phosphorylation (Figures 2(a) and 2(b)).
ADAM17 mRNA is constitutively expressed in normal
adult human kidneys and is increased in disease conditions
[34]. In cultured tubular epithelial cells stimulation with
Aldo rapidly increased ADAM17 gene expression, which
remained elevated up to 24 hours (Figure 3(a)). Among the
EGFR ligands, HB-EGF and TGF-𝛼 are released by ADAM17
and have a role in renal diseases. In tubular epithelial cells,
Aldo upregulated gene expression of HB-EGF and TGF-𝛼,
observed after 3 hours (Figure 3(b)).
TGF-𝛼 blockade, using a specific neutralizing antibody,
inhibited EGFR phosphorylation in response to Aldo in
tubular cells (Figure 4(a)). In contrast, the pharmacological
inhibition of HB-EGF by CRM197, a nontoxic mutant of
diphtheria toxin that neutralizes HB-EGF binding to EGFR
[29], had no effect on Aldo-mediated EGFR activation
(Figure 4(b)).
3.2. Aldosterone Regulates Proinflammatory Gene Expression
via the ADAM-17/TGF-𝛼/EGFR Axis in Cultured Tubular
Epithelial Cells. Aldo exerts proinflammatory actions in the
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Figure 6: Aldosterone activates ERK and STAT pathways via ADAM-17/TGF-𝛼/EGFR axis. HK2 cells were preincubated with (a) the specific
ADAM17 inhibitor TAPI-2 (50𝜇mol/L; 1 hour) or (b) a neutralizing antibody against TGF𝛼 (2.5𝜇g/mL, 24 hour) and then stimulated with
1 𝜇mol/L Aldo for 15min. Figures (a) and (b) show representative Western blot experiment and (c) data expressed as mean ± SEM of 3
experiments. ∗𝑃 < 0.05 versus control. #𝑃 < 0.05 versus Aldo.
kidney, including the regulation of proinflammatory gene
expression in cultured cells [35]; however, the role of the
ADAM-17/EGFR pathway in these Aldo-mediated responses
has not been evaluated. In cultured tubular epithelial cells,
we have blocked ADAM-17/TGF-𝛼/EGFR pathway using the
following inhibitors: the ADAM17 inhibitor TAPI-2, an anti-
TGF-𝛼 neutralizing antibody, and the EGFR kinase inhibitor
AG1478. All of these inhibitors significantly diminished
Aldo-induced gene upregulation of the proinflammatory
factors CCL-2 and CCL-5 (Figure 5).
3.3. Aldosterone Activates Several Intracellular Mechanisms
via the ADAM-17/TGF-𝛼/EGFR Axis. Among the EGFR
downstream signalling mechanisms, activation of the MAPK
cascade has special relevance in the regulation of inflam-
matory events. Aldo increased EGFR phosphorylation on
tyrosine 1068, which has been previously involved in ERK
signalling [29, 34]. In human tubular cells, Aldo increased
ERK phosphorylation and ERK blockade diminished Aldo-
induced proinflammatory gene overexpression (Figure 5).
Moreover, ERK activation was prevented when the ADAM-
17/TGF-𝛼/EGFR pathway was inhibited using the above-
described specific blockers (Figures 6(a), 6(b) and 6(c)).
Aldo also activated STAT-1 via the ADAM-17/TGF-𝛼/EGFR
pathway (Figures 6(a), 6(b) and 6(c)).
3.4. Paricalcitol Inhibits Aldosterone-Induced Proinflamma-
tory Gene Expression in Cultured Renal Cells by Modulating
the ADAM-17/TGF-𝛼/EGFR Axis. In tubular epithelial cells,
preincubation with the VDRA paricalcitol for 48 hours,
inhibited proinflammatory genes induction caused by Aldo
(Figure 7). These data confirm the anti-inflammatory prop-
erties of paricalcitol.
Paricalcitol blocked Aldo-induced EGFR transactivation,
as shown by the downregulation of phosphorylated-EGFR
levels (Figures 8(a) and 8(b)) and ADAM-17/TGF-𝛼 gene
overexpression (Figure 8(c)) to control values.
During renal damage, VDR expression is downregulated
[1, 3]. Interestingly, in tubular epithelial cells Aldo down-
regulated VDR gene and protein levels (Figures 8(a), 8(d),
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Figure 7: Paricalcitol inhibits aldosterone-induced proinflammatory genes in cultured tubular epithelial cells. Cells were pretreated with the
analogue of vitamin D paricalcitol (12𝜇mol/L) for 48 hours before stimulation with 1 𝜇mol/L Aldo for 6 hours. Gene expression levels were
determined by real-time PCR. Data are expressed as mean ± SEM of 3 independent experiments. ∗𝑃 < 0.05 versus control. #𝑃 < 0.05 versus
Aldo.
and 8(e)). Pretreatment with paricalcitol restoredVDR levels,
indicating that beneficial effects of paricalcitol could be due
to modulation of VDR.
Finally, paricalcitol also blocked ERK and STAT-1 activa-
tion in response to Aldo stimulation (Figure 9).
4. Discussion
Chronic inflammation is a main feature of CKD. Among the
factors involved in the inflammatory response in the kidney,
local activation of RAAS has special relevance. AngII, the
main effector peptide of this system, has been extensively
demonstrated to promote renal inflammation [11]. There is
previous evidence that Aldo also contributes to this process.
Multiple experimental studies in models of hypertension,
renal damage, and heart failure have demonstrated that
selectiveAldo blockade by eplerenone attenuates tissue injury
in part by reducing inflammation inAldo target organs [13, 15,
35]. Treatment with an aldosterone synthase inhibitor ame-
liorated experimental diabetic nephropathy by decreasing
renal inflammation, matrix formation, and albuminuria [36].
Data presented here demonstrate that the ADAM-17/TGF-
𝛼/EGFR axis is an important mechanism involved in the
regulation of proinflammatory factors by Aldo in cultured
tubular epithelial cells (Figure 10(a)). Other data also support
the involvement of the EGFR/ADAM17 axis in inflammation
[37, 38], as we have recently described in TWEAK-mediated
experimental renal inflammation [32]. In addition, targeting
ADAM17 by pharmacologic inhibition or gene knockout
attenuates the inflammatory response in animal models of
vascular damage, including hypertension, atherosclerosis,
and pulmonary vascular inflammation [21, 38–40].
EGFR transactivation is regulated by ligand sheddase
activity [41]. Thus far, 12 EGFR ligands have been described,
among them TGF-𝛼, HB-EGF, amphiregulin, and connective
tissue growth factor could be relevant in renal pathology [41–
43]. Regarding the kidney, EGFmodulates glomerular hemo-
dynamics and renal metabolism, while TGF-𝛼, HB-EGF,
and amphiregulin participate in cell survival/proliferation
[41, 43]. Moreover, TGF-𝛼 has been involved in genetic
susceptibility to renal disease [44] and in AngII-mediated
experimental renal fibrosis [20]. HB-EGF contributes to cell
regeneration and repair after ischemia [41]. In HB-EGF-
deficient mice with progressive glomerulonephritis, inflam-
matory renal infiltration and albuminuria were lower which
was ascribed to EGFR pathway inhibition in podocytes [45].
In cultured tubular cells, we have found that Aldo upregulates
both EGFR ligands, TGF-𝛼 and HB-EGF, but only TGF-
𝛼 mediates Aldo-induced EGFR transactivation, at least at
the time point evaluated. This illustrates that EGFR ligands
involved in transactivation are cell and stimuli specific and
indicates that future studies are needed to evaluate the EGFR
ligands involved in Aldo actions in the kidney. In human
renal and cardiovascular pathophysiology, ADAM17 expres-
sion may be increased [21, 34, 46]. Our findings suggest that
Aldo is one of the drivers of increased ADAM17 expression in
tubular cells. Moreover, ADAM17 SNPs have been associated
to increases in cardiovascular mortality [47].
Activation of the RAAS has been associated to acti-
vation of EGFR signalling in renal and cardiovascular
diseases. AngII via EGFR pathway regulates hypertrophy
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Figure 8: Paricalcitol inhibits aldosterone-induced activation of ADAM-17/TGF-𝛼/EGFR signalling pathway. Cells were pretreated with the
analogue of vitamin D Paricalcitol (12𝜇mol/L) for 48 hours before stimulation with 1 𝜇mol/L Aldo for 15min (protein) or 6 hours (gene
studies). Paricalcitol inhibits Aldo-induced EGFR activation (a, b) and gene overexpression of TGF𝛼 and HB-EGF (c). Figure (a) shows a
representative Western blot, in (b) quantification of p-EGFR and in (c) gene expression levels by real-time PCR. Paricalcitol restores Aldo-
induced changes in VDR protein (a, d) and gene (e) expression levels. Figure (a) shows a representative Western blot, in (d) quantification
of VDR protein levels and in (e) gene expression levels. Data are expressed as mean ± SEM of 3 independent experiments. ∗𝑃 < 0.05 versus
control. #𝑃 < 0.05 versus Aldo.
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Figure 9: Paricalcitol inhibits aldosterone-mediated activation of ERK and STAT-1 pathway. HK2 cells were preincubated with paricalcitol
(12𝜇mol/L) for 48 hours before stimulation with 1 𝜇mol/L Aldo for 15min. Figure (a) shows a representative experiment and in (b)
quantification of p-ERK and p-STAT1 expressed as mean ± SEM of 3 independent experiments. ∗𝑃 < 0.05 versus control. #𝑃 < 0.05 versus
Aldo.
and fibrosis in the kidney [20]. In porcine renal proximal
tubular cells HB-EGF shedding-dependent EGFR trans-
activation regulates AngII-induced cell hypertrophy [48].
Interestingly, Smad activation, the main pathway control-
ling fibrosis, is independent of HB-EG/EGFR pathway [48].
In mesangial cells, Aldo activates EGFR linked to ROS
production, ERK signalling, and modulating cell growth
[31], as described in myocytes [49] and vascular cells [50].
In other cell types, Aldo/EGFR may signal through PI3-
kinase/Akt/mTOR/p70S6K1 [22]. We have described here
that, in tubular cells, Aldo activates ADAM17 leading to rapid
and significant activation of EGFR, which in turn activates
downstream cascades, such as theMAPKERK kinase and the
STAT-1 transcription factor (Figure 10(a)).
Several lines of evidence have suggested a potential anti-
inflammatory activity of vitamin D in CKD [6, 19]. In
experimental glomerular diseases and obstructive nephropa-
thy, administration of vitamin D reduces inflammatory cell
infiltration [6–9, 20]. Vitamin D and VDRAs may exert their
immunomodulatory actions by directmodulation of immune
cells, including macrophages, dendritic cells, and T cells
[51]. Vitamin D modulates dendritic cells’ maturation and
function, the population and function of FOXP3+ and IL-
10–producing T regulatory cells [52], and regulates Th17 dif-
ferentiation and decreasses IL-17A production [53]. Besides
regulating immune cells, VDRAs could also exert anti-
inflammatory actions by modulating responses of resident
renal cells. In this sense, we have found that, in tubular epithe-
lial cells, paricalcitol inhibits Aldo-induced proinflammatory
genes upregulation. The mechanisms involved in these anti-
inflammatory effects of vitamin D in epithelial cells are not
well known. In monocytes/macrophages, vitamin D inhibits
LPS-induced cytokine production by upregulating MAPK
phosphatase-1 that inactivates p38 and JNK [54]. In tubular
cells, we found that paricalcitol inhibited Aldo-induced
activation of ERK and STAT-1 (Figure 10(b)), identifying a
novel mechanisms of action of VDRAs.
Earlier studies showed a relation between vitamin D and
EGFR signalling pathways. Those studies were focused on
EGFR binding and regulation of its gene expression [55–58].
After that, many studies demonstrated that vitamin D or
VDRAs increase cell proliferation via EGFR in different
cell types, by a mechanism that includes changes in EGFR
membrane trafficking and downregulation of EGFR growth
signalling [1, 59]. However, recent studies suggest that this
antiproliferative effect could be mediated by the modulation
of the TGF-𝛼/EGFR autocrine growth loop [60]. Our results
show that in cultured tubular epithelial cells, the VDRA
agonist paricalcitol inhibited the EGFR pathway activated by
Aldo bymodulating TGF-𝛼/ADAM17/EGFR signalling path-
way activation and expression, supporting this hypothesis.
5. Conclusions
Our in vitro data in tubular cells stimulated with Aldo
suggest that the anti-inflammatory properties of the VDRA
paricalcitol are, at least in part, mediated by inhibition
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Figure 10: Aldosterone-induced inflammatory responses: role of the ADAM-17/TGF-𝛼/EGFR axis and modulation by paricalcitol. (a)
Aldosterone activates the ADAM-17/TGF-𝛼/EGFR axis to regulate proinflammatory factors. (b) Paricalcitol inhibits aldosterone-induced
activation of ADAM-17/TGF-𝛼/EGFR signalling pathway. MR: mineralocorticoid receptor; VDRA: vitamin D receptor activators.
of the ADAM-17/TGF-𝛼/EGFR and downstream signals,
including ERK and STAT-1. In renal diseases, local activation
of RAAS contributes to inflammation and tissue damage.
Thus, our results show a novel signalling pathway that could
be involved in the observed anti-inflammatory effects of
paricalcitol in CKD and expand the current understanding
of the mechanisms involved in the renoprotective effects of
vitamin D and its analogs.
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